The Thesis
Apellis Pharmaceuticals is a commercial-stage biotechnology business that develops and sells treatments for chronic eye and kidney diseases by inhibiting the complement system. The company generated $1.00 billion in total revenue in 2025, a 28% increase over the previous year, while supporting a market capitalization of $5.3 billion. Reaching GAAP profitability in 2025 marks the structural shift that transforms Apellis from a high-burn research firm into a self-sustaining commercial drug maker.
If you own APLS, you're betting on three specific things.
In our view, there is meaningful upside still ahead, driven by the expansion of the geographic atrophy market where Apellis is the clear leader. The case breaks if safety concerns resurface for its lead eye drug or if its new kidney treatments fail to gain traction with physicians. Both signals will be visible in the quarterly volume of patient start forms. For long-term investors, Apellis is a rare profitable biotech with a dominant position in a massive and largely untreated market.
Numbers at a Glance
What does it do?
Apellis Pharmaceuticals is a growth business that earns money by selling proprietary biologic drugs that block the C3 protein in the human immune system. The company produces SYFOVRE for geographic atrophy, an advanced form of dry age-related macular degeneration that causes blindness, and EMPAVELI for rare blood and kidney disorders. Doctors prescribe these treatments to patients with chronic conditions, and Apellis collects revenue through direct product sales to distributors and specialty pharmacies. Because these are chronic diseases, patients typically require ongoing injections or infusions for years, creating a recurring and predictable revenue stream.
Where does revenue come from?
The vast majority of revenue comes from U.S. sales of SYFOVRE, which accounts for roughly 85% of total product sales. The company splits its business between its ophthalmology franchise for eye care and its systemic franchise for rare blood and kidney diseases. While Apellis sells directly in the United States, it earns royalties and milestone payments from its partner Sobi for sales in international markets. This geographic split allows Apellis to focus its sales force on the high-value U.S. market while capturing global upside through a partner.
Revenue Breakdown
Who are its customers?
Apellis Pharmaceuticals serves retina specialists who treat blinding eye diseases and nephrologists who treat rare kidney conditions. The company reached approximately $587 million in U.S. net revenue for SYFOVRE in 2025, supported by roughly 102,000 doses delivered to physician offices in the final quarter alone. Its eye treatment holds a dominant 60% share of the total geographic atrophy market. For its rare kidney business, EMPAVELI achieved 267 cumulative patient start forms by the end of 2025, representing more than 5% market penetration in its first full quarter post-launch. These figures indicate high physician trust and a rapid adoption curve for its newest indications.
What gives it staying power?
Apellis has a regulatory moat because it was the first company to ever receive FDA approval for a treatment for geographic atrophy. High switching costs protect the business because once a patient begins an injection regimen that effectively slows their vision loss, they are unlikely to switch to a competitor.
Where is it headed?
The company is currently focused on moving EMPAVELI into much larger patient populations for rare kidney diseases like FSGS and DGF. Management is also developing a pre-filled syringe for SYFOVRE to make administration easier for doctors and an AI imaging tool to prove treatment efficacy. If these initiatives work, Apellis will expand from a one-drug success into a diversified platform for immune-mediated diseases.
Apellis has successfully transitioned into a growth phase where revenue is scaling much faster than costs. The 28% revenue growth in 2025 was accompanied by a shift from a $200 million net loss to a $20 million profit. This change suggests the business has reached the scale necessary to cover its heavy research and development bills.
The quality of cash generation is improving as the company reduces its historical reliance on debt and stock sales. Apellis ended 2025 with $466 million in cash, which management believes is sufficient to fund operations until the business is permanently profitable. This internal funding capability is a major milestone for a mid-sized biotechnology firm.
The balance sheet is in a stable position with a debt-to-equity ratio of 1.15x. While the company carries some debt, its massive cash pile and $90.1% gross margins provide a significant buffer against market volatility. The high gross margin allows nearly every new dollar of revenue to flow directly toward operating profit.
Apellis is now a financially self-sustaining business.
SYFOVRE maintains a 60% share of the geographic atrophy market despite facing a newer competitor from Astellas. This dominance is proven by the 17% year-over-year growth in total injection demand. Apellis is successfully defending its first-mover advantage through superior long-term clinical data and deep relationships with retina specialists.
The company must prove it can grow its eye drug revenue without significant price increases as the market matures. Investors should watch the 13% decline in projected 2026 total revenue, which reflects the loss of one-time milestone payments from partners. While product sales are growing, the headline revenue figure may look weaker in the short term as the company laps these large one-time gains.
The geographic atrophy (GA) market is roughly $1.5 billion today and is growing at ~25% annually as the first generation of treatments reaches the ~1 million patients in the United States. This market is expected to exceed $4 billion by 2028 as diagnostic rates improve and international approvals occur. This is a high-quality industry because FDA-approved treatments are rare, providing significant pricing power and structural barriers to entry. Apellis stands as the clear market leader, having launched the first-ever treatment for this condition, which gives it a significant runway to capture newly diagnosed patients. The market is in a land-grab phase where the first-mover typically secures the most loyal physician base.
The competitive dynamic is currently a duopoly in the eye care market but remains a brutal multi-player battle in blood and kidney diseases. Barriers to entry are immense due to the 10-year clinical trial cycles required to bring a drug to market. Long-term pricing power depends entirely on clinical data proving that a drug slows disease progression better than its rivals.
Astellas(ALPMY) is the most dangerous threat because its drug, IZERVAY, offers a similar clinical profile and was launched shortly after SYFOVRE. Roche(RHHBY) and Novartis(NVS) threaten the systemic business by developing more convenient oral or long-acting treatments that could displace EMPAVELI. Astellas is aggressively targeting retina specialists to flip SYFOVRE patients to IZERVAY by highlighting its own safety profile.
Apellis is currently holding its ground with a 60% share of the GA market. The company is successfully defending its territory through long-term extension study data showing its drug becomes more effective over time.
The primary source of protection is Brand & IP, specifically the patents and first-mover regulatory status of pegcetacoplan. Being first to market allowed Apellis to set the standard for how geographic atrophy is treated and measured. The company's 90.1% gross margin is the strongest evidence that its intellectual property allows for premium pricing.
The combination of 90%+ gross margins and an 18.1% ROIC proves that the business model is highly efficient once a drug is approved. These numbers show that Apellis has a real moat that allows it to generate high returns on the capital it spent on research. The 60% market share despite a major competitor launch confirms that switching costs for chronic eye treatments are real.
The moat is currently stable but faces a test as more clinical data from competitors arrives. The most important signal will be whether market share stays above 55% over the next four quarters.
Delivered $1.00B revenue and GAAP profitability in 2025.
Preserved $466M cash to reach self-funded profitability.
Cedric Francois is a co-founder with a significant long-term stake.
Capital Allocation Track Record
Cedric Francois has led Apellis from a startup into a profitable commercial leader by focusing on high-value orphan diseases. The management team has shown significant discipline by reaching profitability without diluting shareholders through massive new stock offerings. By successfully launching two blockbuster-potential drugs back-to-back, management has proven they can navigate both the laboratory and the commercial market.
© 2026 ClearThesis.ai · Report generated on May 27, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.